Cisapride hydrate - CAS 260779-88-2
Catalog number: 260779-88-2
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C23H29N3O4ClFH2O
Molecular Weight:
483.96
COA:
Inquire
Targets:
5-HT Receptor
Description:
Cisapride, also called as R51619, is a serotonin 5-HT4 receptor agonist used as a gastroprokinetic agent. Cisapride stimulates gastrointestinal motility, probably by facilitating acetylcholine release at the myenteric plexus.
Publictions citing BOC Sciences Products
  • >> More
Purity:
≥99%
Appearance:
White to beige solid powder
Synonyms:
4-amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide; hydrate;Cisapridemonohydrate;260779-88-2;cis-4-Amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxybenxamidemonohydrate;CISAPRIDEMONOHYDRATE; 81098-60-4 (Cisapride free base); 189888-25-3 (Cisapride tartrate); 260779-88-2 (Cisapride hydrate)
MSDS:
Inquire
Quantity:
Data not available, please inquire.
InChIKey:
QBYYXIDJOFZORM-IKGOIYPNSA-N
InChI:
1S/C23H29ClFN3O4.H2O/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16;/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29);1H2/t20-,22+;/m0./s1
Canonical SMILES:
COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F.O
1.Alterations in gallbladder emptying and bile retention in the absence of changes in bile lithogenicity in postmenopausal women on hormone replacement therapy.
Dhiman RK1, Sarkar PK, Sharma A, Vasishta K, Kohli KK, Gupta S, Suri S, Chawla Y. Dig Dis Sci. 2004 Aug;49(7-8):1335-41.
The role of female sex hormones in the pathogenesis of gallstones is well established. Pregnancy, contraceptive use, estrogen replacement therapy in postmenopausal women, and estrogen therapy in men for the treatment of prostatic carcinoma have been found to be associated with increased risk of cholesterol gallstones. Alterations in gallbladder emptying and in bile lithogenicity in postmenopausal women receiving hormone replacement therapy (HRT) have not been studied to date. The present study was undertaken to study the effect of HRT on gallbladder emptying and bile lithogenicity. Sixteen postmenopausal women were included in the study. None of the patients had gallstone disease and none had received prokinetic drugs, such as, erythromycin, metoclopramide, domperidone or cisapride, aspirin, and nonsteroidal antiinflammatory drugs. Gallbladder emptying (n = 16), bile microscopy (n = 7), cholesterol saturation index (CSI) (n = 7), and nucleation time (n = 7) were studied before and 3 months after HRT (conjugated estrogen, 0.
2.Review: pathogenesis of gallstones.
Dowling RH1. Aliment Pharmacol Ther. 2000 May;14 Suppl 2:39-47.
The aim of this article is to review selected aspects of the pathogenesis of cholesterol-rich, gall-bladder stones (GBS)--with emphasis on recent developments in biliary cholesterol saturation, cholesterol microcrystal nucleation, statis within the gall-bladder and, particularly, on the roles of intestinal transit and altered deoxycholic acid (DCA) metabolism, in GBS development. In biliary cholesterol secretion, transport and saturation, recent developments include evidence in humans and animals, that bile lipid secretion is under genetic control. Thus in mice the md-2 gene, and in humans the MDR-3 gene, encodes for a canalicular protein that acts as a 'flippase' transporting phospholipids from the inner to the outer hemi-leaflet of the canalicular membrane. In the absence of this gene, there is virtually no phospholipid or cholesterol secretion into bile. Furthermore, when inbred strains of mice that have 'lith genes' are fed a lithogenic diet, they become susceptible to high rates of GBS formation.
3.Pharmacokinetics and tissue distribution of the new gastrokinetic agent cisapride in rat, rabbit and dog.
Michiels M1, Monbaliu J, Hendriks R, Geerts R, Woestenborghs R, Heykants J. Arzneimittelforschung. 1987 Oct;37(10):1159-67.
The plasma kinetics and tissue distribution of the gastrokinetic (+/-)-cis-4-amino-5-chloro-N-[1-(3-(4-fluorophenoxy)propyl]-3-methoxy-4- piperidinyl]-2-methoxybenzamide monohydrate (cisapride, R 51 619) have been studied in the rat, rabbit and dog. After intravenous administration to rats (5 mg/kg) and dogs (0.63 mg/kg) plasma level-time curves were adequately fitted to a two-compartmental model. The plasma clearance (ClT) and volume of distribution (Vdss) averaged 91 ml/min.kg and 4.7 l/kg in the rat and 4.2 ml/min.kg and 0.82 l/kg in the dog, respectively. Following oral administration, cisapride was rapidly and almost completely absorbed from the gastrointestinal tract in rats and rabbits. The absorption was somewhat slower in the dog. In male rats the plasma radioactivity was mainly due to metabolites, unaltered cisapride representing on average 10% of the total radioactivity. A markedly larger proportion of the parent drug was seen in female rats.
4.Effects of 5-HT1A and 5-HT4 receptor agonists on slow synaptic potentials in enteric neurons.
Pan H1, Galligan JJ. Eur J Pharmacol. 1995 May 4;278(1):67-74.
Intracellular electrophysiological methods were used to examine the effects of 5-hydroxytryptamine (5-HT), 5-carboxamidotryptamine (5-CT), 5-methoxytryptamine (5-MeOT), 4-amino-5-chloro-2-methoxy-N-(4-[1-azabicyclo[3,3,1]nonyl]) benzamide hydrochloride (renzapride), cis-4-amino-5-chloro-N[1-[3- (4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl[-2-methoxybenzamide monohydrate (cisapride) and endo-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-3- (1-methyl)ethyl-2-oxo-1 H-benzimidazole-1-carboxamidehydrochloride (BIMU 8) on noncholineric slow excitatory postsynaptic potentials (slow EPSPs) in myenteric afterhyperpolarization (AH) neurons of guinea pig ileum. 5-HT (0.01-1 microM) and 5-CT (0.001-0.1 microM) produced a concentration-dependent inhibition of slow EPSPs. The 5-HT1A receptor antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimidobutyl]piperazine (NAN-190) produced rightward shifts in 5-HT and 5-CT concentration-response curves; facilitation of slow EPSPs was never observed.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related 5-HT Receptor Products


CAS 98206-09-8 Eltoprazine hydrochloride

Eltoprazine hydrochloride
(CAS: 98206-09-8)

Eltoprazine hydrochloride is the hydrochloride form of Eltoprazine which is a serenic or antiaggressive agent. It acts as an agonist at the 5-HT1A and 5-HT1B re...

CAS 132907-72-3 Ramosetron Hydrochloride

Ramosetron Hydrochloride
(CAS: 132907-72-3)

The hydrochloride salt form of Ramosetron, a benzimidazol derivative, could be used to against nausea and vomiting for acting as a 5-HT3 receptor antagonist.

CAS 132414-02-9 Alosetron Hydrochloride(1:X)

Alosetron Hydrochloride(1:X)
(CAS: 132414-02-9)

The hydrochloride salt form of Alosetron, a 5HT3-receptor antagonist, could be used against bowel syndrome.

CAS 123482-23-5 Zatosetron maleate

Zatosetron maleate
(CAS: 123482-23-5)

Zatosetron has been identified as a potent, orally available, long-acting, selective 5HT3 receptor antagonist, which is potentially useful in the treatment of c...

CAS 3880-76-0 8-Methoxy-2-aminotetraline hydrochloride

8-Methoxy-2-aminotetraline hydrochloride
(CAS: 3880-76-0)

8-Methoxy-2-Aminotetraline hydrochloride is a 5-HT1A agonist.

CAS 162760-96-5 WAY-100635

WAY-100635
(CAS: 162760-96-5)

WAY-100635 is an achiral analogue of WAY-100135 which is significantly more potent and selective than the latter compound and which displays unequivocal 5-HTIA ...

Risperidone mesylate
(CAS: 666179-96-0)

Risperidone is a serotonin 5-HT2 receptor blocker and a potent dopamine D2 receptor antagonist.

Elzasonan hydrochloride
(CAS: 220322-05-4)

Elzasonan, also called as CP 448187, exhibits potent and selective antagonism of 5-HT1B receptors in vitro, and preclinical in vivo studies demonstrate enhanced...

CAS 129294-09-3 5-HT3 antagonist 1

5-HT3 antagonist 1
(CAS: 129294-09-3)

A potent and selective antagonist of serotonin 3 (5-HT3) receptor

CAS 740873-06-7 Naluzotan

Naluzotan
(CAS: 740873-06-7)

Naluzotan is a selective 5-HT1A receptor partial agonist under the development of EPIX Pharmaceuticals. It is a serotonergic drug for the treatment of generaliz...

CAS 316-81-4 Thioproperazine

Thioproperazine
(CAS: 316-81-4)

Thioproperazine is a potent neuroleptic with antipsychotic properties, for the treatment of all types of acute and chronic schizophrenia, including those which ...

CAS 132539-06-1 Olanzapine

Olanzapine
(CAS: 132539-06-1)

Olanzapine interacts with key receptors of interest in schizophrenia, having a nanomolar affinity for dopaminergic, serotonergic, alpha 1-adrenergic, and muscar...

CAS 1038988-11-2 5HT6-ligand-1

5HT6-ligand-1
(CAS: 1038988-11-2)

5HT6-ligand-1 is a potent 5-HT6 receptor ligand (Ki= 1.43 nM).

CAS 125926-17-2 Sarpogrelate

Sarpogrelate
(CAS: 125926-17-2)

Sarpogrelate is a drug under the development of Mitsubishi Chemical as 5HT2A and 5-HT2B receptor. antagonists. It is used as an antiplatelet agent and has been ...

CAS 706779-91-1 Pimavanserin

Pimavanserin
(CAS: 706779-91-1)

Pimavanserin is a potent and selective 5-HT2A receptor inverse agonist used in the treatment of Parkinson’s disease psychosis.

CAS 256227-78-8 GMC 2-118

GMC 2-118
(CAS: 256227-78-8)

GMC 2-118 is a potent and selective 5-HT1B antagonist.

CAS 161611-99-0 DU125530

DU125530
(CAS: 161611-99-0)

DU125530 is a selective 5-HT1A receptor antagonist (Ki = 0.7 nM). DU125530 has the potential to be used in the treatment of anxiety, depression and psychiatric ...

CAS 256227-77-7 GMC 2-113

GMC 2-113
(CAS: 256227-77-7)

GMC 2-113 is a selective 5-HT1B antagonist.

CAS 64887-14-5 Urapidil HCl

Urapidil HCl
(CAS: 64887-14-5)

Urapidil HCl is a hydrochloride salt form of urapidil which is α1-adrenoceptor antagonist and 5-HT1A receptor agonist with pIC50 of 6.13 and 6.4 respectively.

CAS 135729-61-2 Palonosetron hydrochloride

Palonosetron hydrochloride
(CAS: 135729-61-2)

Chemical Structure

CAS 260779-88-2 Cisapride hydrate

Quick Inquiry

Verification code

Featured Items